View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 20, 2020updated 07 Sep 2020 5:13pm

Gilead’s remdesivir prevents Covid-19 progression in preclinical study

A preclinical study in the US has found that Gilead Sciences' antiviral drug candidate remdesivir prevented disease progression in rhesus macaques monkeys with Covid-19.

A preclinical study in the US found that Gilead Sciences’ antiviral drug candidate remdesivir prevented disease progression in rhesus macaques monkeys with Covid-19.

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

The animals were infected with the novel coronavirus, SARS-CoV-2.

Data announced by the National Institutes of Health (NIH) revealed a significant decrease in clinical disease and reduced lung damage in monkeys treated with the investigational antiviral drug.

The preclinical study involved dosing and treatment procedures being used in a clinical trial of remdesivir to treat hospitalised Covid-19 patients. NIH’s National Institute of Allergy and Infectious Diseases (NIAID) is leading the trial.

In the preclinical study, one group of monkeys were given remdesivir while the second group acted as an untreated comparison arm, both infected with the novel coronavirus.

The treatment group was administered a dose of intravenous remdesivir 12 hours after infection, followed by a daily intravenous booster dose for the next six days.

According to the NIH, initial treatment was given shortly before the virus reached its highest level in the lungs.

Twelve hours following initial treatment, six treated animals had significantly better health compared to the untreated group. This improvement continued during the seven-day study.

One of the six treated animals had mild breathing difficulty while all six of the untreated animals experienced rapid and difficult breathing.

Also, the amount of virus in the lungs was lower in the treatment group compared to the untreated animals. The findings also showed that the virus led to comparatively less lung damage in treated animals.

Findings from the study have been posted on the preprint website, bioRxiv.

According to investigators, the results indicate that early initiation of remdesivir treatment in Covid-19 patients could result in maximum treatment effect.

Furthermore, scientists said that remdesivir helped prevent pneumonia but did not mitigate virus shedding by the animals.

A statement from the team said: “This finding is of great significance for patient management, where a clinical improvement should not be interpreted as a lack of infectiousness.”

Related Companies

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU